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Abstract
Background: Studies have shown unwarranted variation in test ordering among GP practices and 
regions, which may lead to patient harm and increased health care costs. There is currently no 
robust evidence base to inform guidelines on monitoring long-term conditions.
Objectives: To map the extent and nature of research that provides evidence on the use of 
laboratory tests to monitor long-term conditions in primary care, and to identify gaps in existing 
research.
Methods: We performed a scoping review—a relatively new approach for mapping research 
evidence across broad topics—using data abstraction forms and charting data according to 
a scoping framework. We searched CINAHL, EMBASE and MEDLINE to April 2019. We included 
studies that aimed to optimize the use of laboratory tests and determine costs, patient harm or 
variation related to testing in a primary care population with long-term conditions.
Results: Ninety-four studies were included. Forty percent aimed to describe variation in test 
ordering and 36% to investigate test performance. Renal function tests (35%), HbA1c (23%) and 
lipids (17%) were the most studied laboratory tests. Most studies applied a cohort design using 
routinely collected health care data (49%). We found gaps in research on strategies to optimize test 
use to improve patient outcomes, optimal testing intervals and patient harms caused by over-testing.
Conclusions: Future research needs to address these gaps in evidence. High-level evidence is 
missing, i.e. randomized controlled trials comparing one monitoring strategy to another or quasi-
experimental designs such as interrupted time series analysis if trials are not feasible.
Key words: Chronic disease, common illnesses, continuity of care, diagnostic tests, primary care, scoping review.
Introduction
In primary care, ~50% of laboratory tests are used for monitoring 
long-term conditions (1). Appropriate monitoring ensures early 
detection of disease progression and the development of complica-
tions, potentially enabling GPs to intervene at an early stage, e.g. by 
adjusting treatment. The use of laboratory tests among GP practices 
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and regions varies substantially (2–9), suggesting that chronic dis-
ease monitoring is not optimal in many places. Both over- and under-
testing can cause patient harm and increase health care costs (10,11).
To avoid under- and over-testing, robust evidence is needed 
on what optimal monitoring looks like. Our recent review of UK 
guidelines on monitoring patients with hypertension, type 2 dia-
betes and chronic kidney disease found that most recommenda-
tions were solely based on expert opinion and none had a strong 
evidence base (12).
Guidance on how to generate this evidence base or a framework 
to standardize evaluations of testing strategies are lacking. The aim 
of this scoping exercise is 2-fold. The primary aim is to map the na-
ture, extent and range of research on the use of laboratory tests in 
monitoring long-term conditions in primary care, e.g. which tests 
should be used or not used, how frequently and how can this be 
evaluated. In contrast to a systematic review, we aim to scope the 
methodology used by these studies, i.e. how have researchers tried 
to answer these questions, instead of extracting their research find-
ings. The secondary aim is to identify gaps in existing research, i.e. 
identifying questions that are not being addressed. Because we are 
addressing a broad topic from different angles, where study design 
is an outcome rather than an inclusion criterion, we considered a 
scoping review approach to be most suitable.
Methods
A scoping review is a relatively new but increasingly used method 
for mapping research evidence across broad topics. This scoping re-
view is reported according to the PRISMA Extension for Scoping 
Reviews reporting guidelines (13). The review protocol is available 
online (14).
Sources of evidence
We searched CINAHL, EMBASE and MEDLINE to April 2019. The 
search included terms for specific long-term conditions (e.g. hyper-
tension, diabetes, chronic kidney disease), monitoring tests (e.g. 
glucose, lipids, creatinine, HbA1c) and primary care (see protocol ap-
pendix for detailed search strategy) (14). Search terms were adapted 
for each database. We did not apply any language restrictions.
Study selection
Studies that fulfilled the following criteria were eligible for inclu-
sion: primary care setting, adult patients (>18 years of age) with non-
communicable long-term conditions (e.g. cardiovascular disease, 
chronic kidney disease and type 2 diabetes), laboratory tests (e.g. 
urine and blood tests) and aiming to address any of the following 
questions (Fig. 1):
• How can testing for chronic disease monitoring be optimized? 
(i.e. studies that present strategies or methods to define or 
evaluate optimal testing)
• Which test should be used for monitoring? (i.e. studies on test per-
formance or appropriateness)
• How frequently should patients be monitored?
• What are possible harms to patients of under- or over-testing?
• What are the costs of under- or over-testing?
• How does monitoring vary (e.g. by region, sex or age)?
We did not apply any restrictions on study design or outcome 
measures. Studies investigating a general population, patients with 
infectious diseases or patients with mental health disorders were ex-
cluded. Publications that did not use a methodology (e.g. editorial) 
were also excluded, whereas papers that reported on methodology 
but not on research findings were included (e.g. protocols).
Identified papers were screened independently by at least two re-
viewers (ME, LS and KA) using Rayyan (15). Discrepancies were re-
solved through consensus or a third reviewer (PW). Foreign language 
records were translated and assessed by the review team.
Data abstraction
Data were abstracted using standardized forms developed in Google 
Forms. Forms were piloted on a small sample of studies and adapted 
as necessary. The form included study characteristics (first author, 
year of publication, geographical location of study population), 
study aims, population details (which chronic disease(s) and sample 
size), methodology (study design and statistical methods), moni-
toring test and outcome measures. In order to minimize bias and 
errors, data abstraction was performed by one reviewer and checked 
by a second reviewer (ME and LS). Disagreements were resolved 
through discussion or referral to a third reviewer where necessary. If 
full texts were unavailable, data were abstracted from the abstract 
where possible.
Synthesis
The results are described and charted according to the scoping frame-
work published by Arksey and O’Malley (16) and guidance by Peters 
et al. (17). An overview of the volume and nature of available evidence is 
represented graphically using tables and charts. Several simplifications 
were made in order to categorize variables and visualize them in charts. 
For instance, ‘hepatic injury’ and ‘liver cirrhosis’ were categorized as 
‘liver disease’, and ‘glomerular filtration rate’ and ‘microalbuminuria 
tests’ were categorized as ‘renal function tests’. Most categories were 
predefined in the data abstraction form (14), although some extra 
categories were added based on the data. For example, ‘response to test 
results’ (e.g. whether the clinician adjusted the medication in response 
to the test results) was included as an outcome category because it was 
identified during data abstraction and did not fit into any existing cat-
egory. Sparse or unclear data were put in an ‘other’ category.
Results
The database search yielded 12 061 citations; of which, 8243 were 
unique. Seven thousand nine hundred and thirty-three citations 
Key Messages
• Optimal testing for chronic diseases is an area of uncertainty in primary care.
• The uncertainty causes unwarranted variation in test ordering among GP practices.
• We identified gaps in research on determining the optimal frequency of testing.
• Optimal testing strategies improve patient outcomes and reduce patient harms.
•  To optimize testing strategies, high-level evidence is needed.
• Ideally, by running randomized controlled trials or quasi-experimental designs.
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were excluded based on title and abstract. The remaining 310 cit-
ations underwent full-text review. At the full-text screening stage, 
216 papers were excluded based on publication type (no methods 
reported, e.g. editorial), setting, monitoring test, population or no 
abstract available (Fig.  1). Ninety-four studies were included in 
the scoping review (Fig. 1) (8,18–109), including seven studies for 
which full texts could not be retrieved, so data were abstracted 
from the abstract (101,102,104,106–109). Six included non-English 
papers were in French, German, Hebrew, Hungarian, Polish and 
Portuguese, which were translated and assessed by the review team 
(34,40,110–113).
Studies were labelled with one or more of the six prespecified 
study aims (Fig.  1). The key questions ‘How can testing for 
chronic disease monitoring be optimized?’ (i.e. studies that pre-
sented strategies to optimize testing) and ‘how frequently should 
patients be monitored?’ were addressed by only 12 studies (18–
20,22,35,37,50,51,63,64,72,93) and 11 studies (22,33,46,47,49,52
,56,72,82,84,99), respectively. Studies labelled as ‘which test should 
be used for monitoring’ (n = 34) focussed on the diagnostic perform-
ance of specific monitoring tests instead of test appropriateness (e.g. 
whether performing the test improves patient outcomes). The most 
common aim was ‘how does monitoring vary’ (n  =  38), in which 
studies described the variation in monitoring between regions, pa-
tient subgroups or over time. Three studies investigated the costs of 
over-testing, but none of the studies reported on the possible harms 
of over-testing to patients (34,78,105).
Seventy studies (74%) were published within the last 10 years 
(Fig.  2A, Supplementary Table 1). The selected studies included 
62 (66%) original research reports, 19 (20%) conference ab-
stracts or posters, 8 (9%) reviews (including 5 systematic reviews 
(8,31,47,52,80) and 3 narrative reviews (33,50,63)), 4 protocols 
(21,27,71,90) and 1 PhD thesis (38) (Fig. 2B). More studies were 
based in the UK (18%) and the USA (17%) than elsewhere (Fig. 2C, 
Supplementary Table 1).
The majority of studies focussed on diabetes (51%), especially 
type 2 diabetes (40%), followed by hypertension (11%) and rheuma-
toid arthritis (10%) (Fig. 3A). In nine studies, the study population 
consisted of patients on a certain type of medication, e.g. patients 
on statins (23,46,51), warfarin (90,104,108,109) or ‘high risk medi-
cation’ (55). Population sizes varied from 6 (89) to 2,395,340 (23) 
patients (Fig. 3B).
Forty-eight studies (49%) employed a retrospective cohort de-
sign, using routinely collected data and large sample sizes (>1000). 
Other study designs included prospective cohort design (23%), re-
views (11%), early-stage diagnostic studies (5%) (45,61,89,98,114), 
randomized controlled trials (2%) (22,108) and case–control de-
sign (2%) (44,84) (Fig. 4A). Many studies solely used descriptive 
statistics to explore the data (28%). These were mainly the studies 
investigating variation in monitoring. Many studies (39%) used 
some form of modelling, e.g. regression analysis. Studies looking at 
test performance, either used correlations (i.e. measuring the correl-
ation between an old and a new test) or formal diagnostic accuracy 
Figure 1. PRISMA flow diagram. Some studies had more than one aim and appear more than once in under ‘study aims’ in this diagram.
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measures (i.e. estimating sensitivity and specificity of a new test 
against a reference standard) (Fig. 4B).
The most frequently studied laboratory tests were renal func-
tion tests (35%), including estimated glomerular filtration rate, cre-
atinine, urea, potassium and proteinuria, followed by HbA1c (23%) 
and lipids (17%). Other tests that were less common, were liver 
function tests (including liver enzymes, 99mTc-Hepida plasma clear-
ance and bilirubin), blood glucose, clotting tests, thyroid and natri-
uretic peptides (Fig. 5A).
Thirty-six studies (38%) reported ‘rate of monitoring’ as the 
primary outcome. These were studies aiming to show the variation 
in monitoring and often compared the actual rate of monitoring to 
what is recommended in current guidelines (‘compliance with guide-
lines’) (Fig. 5B). Thirteen studies (14%) reported patient outcomes (1
8,19,22,30,60,70,71,82,84,90,93,103,115), such as disease progres-
sion or incidence of complications. Seven studies (7%) reported costs 
as the outcome (34,52,76,78,92,99,105), such as cost-effectiveness 
of a screening program for certain patient subgroups. Two studies 
Figure 3. Population characteristics included disease groups (A) and size of study population (B). Not applicable (NA), if there were no patients included in the 
study, such as in reviews or studies using simulated data.
Figure 2. Characteristics of included studies: year of publication (A), publication type (B) and location (i.e. origin of study population) (C). Not applicable (NA), if 
there were no patients included in the study, such as in reviews or studies using simulated data.
4 Family Practice, 2020, Vol. XX, No. XX
D
ow
nloaded from
 https://academ
ic.oup.com
/fam
pra/advance-article/doi/10.1093/fam
pra/cm
aa074/5895229 by U
niversity of Bristol Library user on 03 Septem
ber 2020
investigated the response to test results (51,72), i.e. whether to the 
clinician acted on the abnormal test results. Although one study re-
ported patient harms associated with not-testing, i.e. incidence of ad-
verse outcomes in patients who were not monitored regularly (77), 
none of the studies investigated patient harms due to over-testing.
Discussion
Most research on laboratory test monitoring of long-term condi-
tions either describes the variation in monitoring or reports the test 
performance of specific tests. This does not address the fundamental 
question of whether the test is necessary or beneficial.
The most important reason for monitoring is to improve patient 
outcomes, especially due to early intervention. Nevertheless, only a 
few studies reported on this outcome. Another important outcome 
is whether GPs responded to an abnormal test results because moni-
toring tests are only useful if the result informs patient treatment. 
However, only two studies investigated this outcome. Finally, over-
testing can cause harms to patients (116), but none of the included 
studies investigated this.
Figure 4. Methodology of included studies: study design (A) and statistical methods (B).
Figure 5. Tests (A) and reported outcome measures (B) of included studies.
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Most research on optimal testing focusses on patients with type 
2 diabetes, testing for renal function and HbA1c. The most common 
study design was retrospective cohort design using routinely col-
lected data, followed by prospective cohort design. Outcomes were 
often summaries of current practice compared to guideline recom-
mendation or test performance, i.e. whether a new test works just as 
well as the old test.
This scoping review has identified several gaps in the literature. 
More evidence is needed on establishing the best testing interval, 
and what the harms of under- and over-testing are, as well as what 
strategies or methods can successfully optimize testing to improve 
patient outcomes. We believe that the best study design to obtain 
the highest level of evidence on optimal testing is a randomized or 
cluster randomized controlled trial including an economic evalu-
ation of cost-effectiveness. For instance, patients or GP practices can 
be randomized to different testing strategies based on comparing 
different testing strategies comprising different testing sets and dif-
ferent testing intervals. Important outcomes to consider would be 
(i) testing rates, (ii) adverse outcomes specific for the disease (such 
as disease progression), (iii) harms to patients due to testing (such 
as patient anxiety and unnecessary follow-up testing) and (iv) costs 
(such as health care usage, GP workload). While some of these out-
comes would be expected to show changes within short time period 
(<12 months), for example testing rates, other outcome such as dis-
ease progression will require longer follow-up periods.
The second-best approach is to use a quasi-experimental design, 
comparing the effect of an already implemented policy change (such 
as the publication of new testing guidelines). Routinely collected pri-
mary and secondary care data could then be used to perform an 
interrupted time series analysis. However, this is problematic be-
cause GP practices do not strictly follow the guidelines on testing 
and the guidelines often do not give clear recommendations (12). 
Alternatively, a new testing strategy could be implemented in one 
area and compared to a demographically similar region. These ap-
proaches may be cheaper but can still be time consuming because a 
long follow-up will be needed and are more prone to bias.
Finally, a retrospective comparative cohort study using rou-
tinely collected health care data may give some insight on the 
benefits of using ‘a lot of tests’ versus using ‘a minimal number of 
tests’ and ‘frequent testing’ versus ‘applying longer testing inter-
vals’. Because of the large variation in testing between GP prac-
tices, irrespective of the demographics of the population that they 
serve, these practices could be divided into practices that tend to 
test often and practices that tend to test less. Patients from ‘high’ 
and ‘low’ testing practices could be matched, i.e. on demographic 
factors, co-morbidities and disease severity. The differences in ad-
verse outcomes specific for the disease and health care usage be-
tween both groups could be investigated. Although this approach 
would be much cheaper and time-saving, it will be difficult to 
investigate patient harms due to over-testing (especially patient 
anxiety or unnecessary follow-up testing) and it will be impos-
sible to control for all possible biases.
The main strengths of this scoping review are that we have used 
a very broad search and inclusion criteria and did not restrict by lan-
guage or publication date. To our knowledge, this is the first scoping 
review on methods used to create an evidence base underlying 
chronic disease monitoring in primary care.
The purpose of this scoping review was to map the main sources 
and types of evidence available; therefore, the findings of the indi-
vidual studies were not extracted or analysed. Studies on secondary 
care populations were excluded, which is a limitation of this re-
view. Gaps identified in the primary care literature may have been 
addressed in secondary care, although their results may not neces-
sarily be applicable to the primary care setting. Another limitation 
is that we excluded studies that included a general population, i.e. 
those investigating how to optimize screening, and focussed on 
studies investigating populations with long-term conditions. These 
studies may have used methods that are also relevant to monitoring 
chronic disease populations.
Future research in this area needs to address these gaps in evi-
dence. High-level evidence is missing, i.e. randomized controlled 
trials comparing one monitoring strategy to another or quasi-
experimental designs such as interrupted time series analysis if trials 
are not feasible. Methods and reporting guidelines should be devel-
oped for studies evaluating optimal testing for long-term conditions. 
This will improve the quality of evidence, as well as reproducibility 
and transparency of future research and could serve as a framework 
to judge the trustworthiness of research findings. For clinicians, ap-
propriate tests and testing frequencies can only be identified if we 
know whether testing improves patient outcomes and whether the 
benefits outweigh patient harms. Until better evidence is available, 
decisions around testing should be a collaborative process between 
patients and clinicians. These decisions should be informed by the 
patients’ personal preferences and views in combination with cur-
rent guidelines.
Supplementary material
Supplementary material is available at Family Practice online.
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